Atterocor Begins ACC Trial

Atterocor, Inc. has initiated a Phase I trial of ATR-101 for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a novel, oral drug candidate that has shown selective effects on cells derived from the adrenal cortex in a variety of preclinical studies.

Atterocor’s first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced ACC, whose disease has progressed on standard therapy. Tumor and biomarker responses will also be observed. The Phase I trial is being conducted at the University of Michigan Comprehensive Cancer Center in Ann Arbor and The University of Texas MD Anderson Cancer Center in Houston, and expects to enroll 21 patients.

ATR-101 has received Orphan Drug Designation from both the FDA and EMA. ACC is often fatal and affects approximately 1,000 patients in the U.S.